Drugs / clopidogrel bisulfate
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (3) | US (FDA) | PLAVIX | — | 2002-02-27 – 2011-05-06 | fda.gov ↗ |
| Approved | US (FDA) | PLAVIX | — | 1997-11-17 | fda.gov ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00020189 | Jun 2000 → Aug 2004 | head and neck cancer, thrombotic disease | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT01431495 Comparator | Apr 2010 → Jun 2011 | coronary artery disorder | Les Laboratoires des Médicaments Stériles | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | clopidogrel bisulfate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00020189 ↗ |
| Known as | Pidogrel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01431495 ↗ |
| Route | Oral | “Patients also receive oral aspirin and clopidogrel bisulfate beginning on day 0 and continuing throughout the study.” NCT00020189 ↗ |